Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of ADI-PEG 20 in Advanced Hepatocellular Carcinoma
2011-002041-36Phase 3Completed
- Sponsor
- Polaris Group
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing ADI-PEG 20 with Placebo (2 arms). Primary endpoint: Overall survival. Started Jun 2011; status: completed.
02
Drugs
Pegargiminase
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2011-002041-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002041-36.